ZKZvonimir Krajcer

Zvonimir Krajcer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zvonimir Krajcer has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In Memoriam: Alain G. Cribier, MD

    by Zvonimir Krajcer

    Alain G. Cribier, MD, the French interventional cardiologist who pioneered the first balloon dilatation of the aortic valve for the treatment of calcific

  • Open Access

    General versus Local Anesthesia with Intravenous Sedation in Transcatheter Aortic Valve Implantation

    by Alexander Schutz, Zvonimir Krajcer, Qianzi Zhang, Scott A. LeMaire, Katherine G. Dougherty, Juan Carlos Plana, Stephanie A. Coulter, Neil E. Strickman, Guilherme V. Silva, James Anton, et al.

    Background. Monitored anesthesia care (MAC) may offer better outcomes than general anesthesia (GA) in transcatheter aortic valve implantation (TAVI). We compared TAVI outcomes between patients who received MAC versus GA. Methods. We retrospectively reviewed data from all patients (N = 659), as well as 216 propensity-matched patients, who underwent TAVI at our institution during 2014–2019. Results. MAC and GA did not differ significantly in mortality (1.6% MAC vs. 4.2% GA, = 0.05) or stroke (2.2% MAC vs. 2.4% GA, = 0.96); however, median length of stay (LOS) was shorter in the MAC group (2 d MAC vs. 7 d GA, < 0.0001). In propensity-matched patients, mortality (2.8% MAC vs. 4.6% GA, = 0.7) and stroke (3.7% MAC vs. 1.9% GA, = 0.7) did not differ significantly between groups. LOS remained shorter in the MAC group (2 d MAC vs. 7 d GA, < 0.0001). Conclusions. In this large, single-center, retrospective study, MAC was associated with shorter hospital stay after TAVI.

  • Open Access

    The Role of Transcatheter Aortic Valve Implantation in Patients With Bicuspid Valves in 2023

    by Milad El Hajj, Zvonimir Krajcer

    Bicuspid aortic valve (BAV) is the most common congenital heart defect, occurring in 1% to 2% of the general population.1 Compared with individuals having normal tricuspid aortic valves, those with BAVs are more likely to develop calcification on valve leaflets and raphe and dilation of the ascending aorta (aortopathy)—and at a much earlier age. For highly select patients with severe BAV stenosis, transcatheter aortic valve implantation (TAVI) may be a feasible alternative to surgical repair or replacement.2–4 Newer-generation replacement valves, such as the balloon-expandable SAPIEN-3 (Edwards Lifesciences) and the self-expanding Evolut R/Pro (Medtronic, Inc) valves, are approved by the US Food and Drug Administration for all surgical indications regardless of valve anatomy, including BAV.5,6Pivotal randomized controlled trials for TAVI in tricuspid aortic valve stenosis2–4 have excluded BAV stenosis; nonetheless, studies of real-world registry data suggest comparable outcomes and similar short-term (30-day) mortality for TAVI in patients with BAV stenosis,7,8 although patients with BAV stenosis who underwent TAVI had a higher 30-day stroke rate (2.5% vs 1.6%; hazard ratio, 1.57 [95% CI, 1.06–2.33]).7 These studies are limited by their observational nature and did not account for various BAV morphologies. Moreover, future randomized clinical trials of BAV and TAVI are unlikely, given that TAVI is now an approved, widely used procedure.The optimal sizing methodology for BAV has not been resolved. The Sievers classification9 is the most widespread proposal for BAV morphology and is based on 3 characteristics: the number of raphes, the spatial position of cusps or raphes, and the functional status of the valve. Although the Sievers classification has historically been used to guide surgical BAV replacement, its utility in TAVI is limited.Within the traditional Sievers classification scheme, BAV phenotypes are categorized according to the number of raphes (0, 1, or 2). However, this scheme does not account for several unfavorable features of BAV anatomy that warrant special consideration before TAVI. Such features in BAV include a frequently encountered more elliptical annulus, asymmetric and more extensive calcium distribution, calcification extending into the left ventricular outflow tract (LVOT), closer proximity to the coronary ostia (with potential coronary artery occlusion), and more common ascending aorta dilatation (more frequently found in patients with 2 raphes10). Overall calcium burden, particularly in the presence of calcified raphes, may hinder optimal valve expansion and promote perivalvular leak.Yoon et al10 proposed a novel classification scheme that may provide better risk stratification of patients with BAV stenosis who are being considered for TAVI. In their scheme, the Sievers classification is initially used to describe the presence, number, and spatial position of raphes. Then, in patients with raphes, calcification in the leaflets, raphe, and LVOT are assessed and graded, and patients can be categorized into 1 of 3 groups: no calcified raphe and no excess leaflet calcification, calcified raphe or excess leaflet calcification, or calcified raphe plus excess leaflet calcification.Using this new classification scheme, the authors evaluated the association of BAV morphology and outcomes of TAVI with the new-generation Evolut R/Pro and SAPIEN 3 devices. Multivariate analysis identified calcified raphe and excess leaflet calcification as independent predictors of 2-year all-cause mortality in patients with BAV undergoing TAVI, compared with patients having 1 or none of these features (25.7% vs 9.5% vs 5.9%, respectively; P < .001; see Fig. 1).10 Furthermore, patients with both morphologic features had higher rates of aortic root injury, moderate to severe paravalvular regurgitation, need for reintervention, and 30-day mortality.10Other recent studies further corroborate these findings, suggesting that TAVI is feasible in patients with low-risk BAV stenosis. The Low-Risk Bicuspid Study found that the Evolut R/Pro system was both safe and feasible in 150 patients with BAV without aortopathy or LVOT calcification.3 An analysis of the PARTNER 3 trial bicuspid registry found similar outcomes with the SAPIEN 3 valve between 148 patients with BAV without extensive raphe or subannular calcification and a propensity-matched cohort of patients with tricuspid aortic valve stenosis.11The present consensus is that patients aged 65 years or younger and patients with an aortic diameter greater than 45 mm are better candidates for surgery than TAVI.12More data are needed to elucidate the role of TAVI for patients with BAV and problematic anatomical features. Further modifications in endoprosthesis design are needed to reduce the incidence of complications such as perivalvular aortic insufficiency, annulus rupture, and coronary ostial obstruction for patients with BAV who undergo TAVI. It is hoped that, in the future, the information gathered through registries will further elucidate the best strategy for TAVI for patients with BAV. The implementation of artificial intelligence in preprocedural planning can assist with visualizing areas of potential risk and has been of significant help in device selection and preventing some of the most common complications for patients undergoing TAVI.13

  • Bioresorbable stents: We have more work to do

    by Milad El Hajj, Zvonimir Krajcer

    Key Points: The NeoVas sirolimus‐eluting bioresorbable stent is safe and efficacious for treating de novo coronary artery disease. Lesion and patient‐specific characteristics may play a role in the long‐term safety profile of bioresorbable stents. The role of bioresorbable scaffolds in complex coronary lesions needs to be further elucidated.

  • The relationship between chronic kidney disease and “complex” percutaneous coronary intervention: Uncovering the details

    by Alexander Postalian, Zvonimir Krajcer

    Key Points: It remains unclear whether the complexity level of coronary interventions affects cardiovascular outcomes in patients with chronic kidney disease (CKD). This study showed that “complex” percutaneous coronary intervention (PCI) is associated with a greater risk of adverse cardiovascular events than standard PCI in both patients with or without CKD. However, the complexity of PCI appeared to have a greater effect on all‐cause mortality and bleeding in patients with CKD than in those without CKD. The data presented confirm the predicted effect of CKD on outcomes after complex PCI. However, the similar effect of complex PCI observed in patients with or without CKD suggests that some patients with CKD have an acceptable risk profile to undergo complex intervention. The reported findings should be interpreted with caution; making a patient‐specific decision before PCI is key in this patient population.


  • A roadmap to arrhythmias after transcatheter pulmonary valve replacement in pediatric patients

    by Milad El Hajj, Zvonimir Krajcer

    Key Points: In pediatric patients undergoing balloon‐expandable transcatheter pulmonary valve replacement within the native right ventricular outflow tract (RVOT), postprocedural ventricular arrhythmias were common and occurred in 33% of patients. Patients with postprocedural ventricular arrhythmias had a benign course, and all patients with follow‐up were successfully weaned off antiarrhythmic therapy. Patients with previous transannular patch repairs in the RVOT had an overall lower ventricular arrhythmia burden.

  • Percutaneous tricuspid valve repair: A safer alternative to traditional approaches?

    by Milad El Hajj, Zvonimir Krajcer

    Key Points: The use of the PASCAL transcatheter valve repair system is a safe and feasible approach for treating patients with severe, symptomatic tricuspid regurgitation and is associated with improved quality‐of‐life outcomes at 30 days. The TriCLASP study adds to the growing body of evidence supporting the use of transcatheter tricuspid valve interventions for treating severe tricuspid regurgitation in high‐risk surgical patients. In the highly anticipated CLASP II TR pivotal trial (NCT04097145), patients will be randomized to receive treatment with the PASCAL system and optimal medical therapy or optimal medical therapy alone.

  • Open Access

    A Minimalist Transcatheter Aortic Valve Replacement Approach: Safety and Effectiveness in Real-World Practice

    by Zvonimir Krajcer

    Transcatheter aortic valve replacement (TAVR) is a well-established therapy for severe, intermediate-risk, and low-risk aortic stenosis.1,2 Until recently, TAVR-related patient selection, anesthesia choice, procedural steps, postprocedural care, and outpatient follow-up varied widely among institutions. Some of these differences may contribute to complications, prolonged hospital stays, and increased expenditures.Minimalist TAVR has been popularized by many investigators as a way to improve patient satisfaction and reduce hospital expenditures. To achieve these goals, the procedure is typically performed in the cardiac catheterization laboratory—which is less expensive than using a hybrid surgical suite—with conscious sedation and a percutaneous femoral artery approach; this is followed by postprocedural monitoring on a telemetry ward rather than in a more costly intensive care unit (ICU) to reduce the length of hospital stay to 24 hours.We retrospectively reviewed the electronic health records of patients who underwent TAVR performed by 2 high-volume operators from March 2015 through February 2020 at the Texas Heart Institute and CHI St Luke's Health–Baylor St Luke's Medical Center. Of 1,154 total procedures, 561 (48.61%) qualified as minimalist TAVR. Two contraindications to minimalist TAVR were severe underlying pulmonary disease and the inability to obtain adequate surface transthoracic echocardiograms for valve evaluation after deployment.The patients' mean (SD) age was 78 (9.1) years, and their mean (SD) Society of Thoracic Surgeons Predicted Risk of Mortality score was 5.7% (3.6%). Only 7 patients (1.2%) needed conversion to general anesthesia, and 23 patients (4%) required transfer to an ICU. Hospital mortality was 0. Complications within 30 days included new permanent pacemaker implantation in 44 patients (7.8%), major vascular complications in 12 patients (2.1%), and clinically manifested stroke in 6 patients (1%). The median postoperative hospital length of stay was 1.8 days.We found that minimalist TAVR was associated with a relatively short and uncomplicated hospital stay and a low rate of adverse events. Our findings compared favorably with findings from large intermediate-risk and low-risk1,2 device trials conducted by Edwards Lifesciences and Medtronic as well as with the data reported by the Vancouver Multidisciplinary, Multimodality, but Minimalist (3M) investigators.3This observational study had several limitations, including that the procedures were performed by only 2 operators at a single center, so the broader application of our data is limited. In addition, the comparison of data between studies has its faults because of the differences in study methodology and patient characteristics.We conclude that minimalist TAVR is safe and effective in real-world practice, and it does not require a complicated preoperative patient selection process. Team discussion is essential regarding the use of conscious sedation and femoral artery percutaneous access with the intent to discharge the patient early.Conflict of Interest Disclosure: NoneFunding/Support: NoneMeeting Presentation: Presented at the Inaugural Global Cardiovascular Forum, 26 February 2022, Houston.

  • Mitral annular calcification—A marker of risk, and a harbinger of technical challenges during intervention

    by Alexander Postalian, Zvonimir Krajcer

    Key Points: Mitral annular calcification (MAC) is a marker of high cardiovascular risk, as well as an obstacle to procedural success during mitral valve surgery. This pathology leads to low intervention rates, even in symptomatic patients. The authors find that, in carefully selected patients with MAC, mitral valve surgery can produce adequate results and should be pursued when indicated. The procedural results and clinical benefits of transcatheter edge‐to‐edge mitral valve repair (TMVr) in this cohort of patients treated between 2015 and 2016 were less than satisfactory, and no better than those of medical therapy. Further TMVr technical refinements are necessary before this technique can benefit patients with mitral valve dysfunction

  • Sex‐based differences in patients undergoing transseptal transcatheter mitral valve replacement: Closing the sex disparity gap

    by Matthew W. Segar, Zvonimir Krajcer

    Key Points: In a nationwide registry of more than 2000 hospitalizations, the proportion of women undergoing transseptal transcatheter mitral valve replacement increased from 50.0% in 2015 to 60.2% in 2018. No significant differences were observed between sexes for complications, hospital length of stay, or in‐hospital mortality rate. Women had a higher 30‐day readmission rate and were more likely than men to be discharged to a skilled nursing facility.